These findings support multidisciplinary care as the cornerstone of long-term survival in liver cancer as an integral component of immunomodulation, DC-CIK cell therapy remodels the tumor microenvironment to facilitate other treatments, making it a defining therapeutic decision for patients with advanced liver cancer.
Abstract
Pancreatic cancer is widely acknowledged as one of the most aggressive malignancies of the digestive system. More than 80% of patients are diagnosed at an advanced stage with an extremely poor prognosis. While contemporary combination chemotherapy and the novel RAS inhibitor daraxonrasib have modestly prolonged survival, clinical benefits remain limited, necessitating less toxic yet more substantial and durable therapeutic strategies. Herein, we report a case of a patient with advanced metastatic adenocarcinoma who achieved disease stability and long-term survival following multidisciplinary treatment incorporating autologous DC-CIK cell therapy. The patient was a 73-year-old male diagnosed with poorly differentiated pancreatic ductal carcinoma 9 years ago. After surgery, he developed pelvic implantation metastases and subsequently received multi-line chemotherapy and radiotherapy. Thereafter, he completed five cycles of DC-CIK cell infusion at a dose of 5×109 ~10×109 cells between November 2018 and December 2019. The patient did not experience any obvious adverse reactions during the treatment. Post-treatment, the patient maintained a stable disease state. Although bone metastasis was detected in February 2021, the patient’s overall survival (OS) and progression-free survival (PFS) reached 107 and 49 months, respectively, far exceeding those previously reported in the literature. Furthermore, the patient experienced an improvement in quality of life. These findings support multidisciplinary care as the cornerstone of long-term survival in liver cancer. As an integral component of immunomodulation, DC-CIK cell therapy remodels the tumor microenvironment to facilitate other treatments, making it a defining therapeutic decision for patients with advanced liver cancer.
Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of non-small-cell lung cancer, characterized by high invasiveness and treatment resistance. Patients with PSC often exhibit poor treatment outcomes, short median survival and a dismal prognosis, necessitating novel comprehensive treatment strategies to address thi...
Zi-Jian Qiu, F. Xuan, Xi-Lan Mao et al.· Oncology Letters· 0 citations
Rationale: Renal cell carcinoma is a highly heterogeneous urological malignancy, with clear cell renal cell carcinoma (ccRCC) as the most common pathological subtype. A considerable proportion of patients are diagnosed at advanced stages or experience postoperative recurrence and distant metastasis, leading to poor lon...
The progress in the treatment modalities for SCLC is focused on and future perspectives involving novel therapeutic combinations, assessment of new targets, and strategies to overcome treatment resistance are discussed.
Xiangwei Cheng, Weibin Lv, Linfeng Wu et al.· Journal of Cancer Research a...· 0 citations
SMARCA4-deficient non-small cell lung cancer (SD-NSCLC) is a highly aggressive molecular subtype. This malignancy is often diagnosed at an advanced stage, carrying a dismal prognosis and also demonstrating poor responsiveness to traditional treatment. Beyond its primary site, the disease can exhibit unusual metastatic...
T. Bu, Nan Zhang, T. Jin et al.· Frontiers in Oncology· 0 citations
Introduction Soft tissue sarcomas (STS) are rare mesenchymal malignancies with limited treatment options in advanced stages. Anthracycline-based chemotherapy remains the standard of care but yields modest outcomes with significant toxicity, underscoring the need for more effective strategies. Methods We retrospectively...
Zhi-Chao Liao, Jun Huang, Hao-Tian Liu et al.· Frontiers in Immunology· 0 citations
Brain metastases from non-small cell lung cancer are typically managed with local therapies, such as surgery and radiotherapy, whereas systemic treatments have historically demonstrated limited efficacy in the intracranial setting. Immune checkpoint inhibitors, particularly programmed cell death-1 inhibitors, have rece...
Ryuichi Noda, A. Akabane, Mariko Kawashima et al.· NMC Case Report Journal· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.